Abstract

THE COMPATIBILITY OF ATRYN (ANTITHROMBIN [RECOMBINANT]) WHEN COADMINISTERED IN AN INTRAVENOUS LINE ALONG WITH COMMONLY USED MEDICATIONS

Sean Evans*, Sharon Malia and Nick Masiello

ABSTRACT

ATryn (antithrombin [Recombinant]) concentrate (rhAT) can restore antithrombin levels in deficient patients, and is approved for administration using intravenous (IV) infusion. This study was undertaken to understand the effects on rhAT when infused in a common IV line with other medications via a Y-connector. The biochemical effects on rhAT when individually co-administered with 18 target medications via syringe pump at a medically therapeutic infusion rate were evaluated using a battery of assays measuring rhAT quality attributes. Sixteen of the 18 commonly used medications in this study did not affect the quality attributes of rhAT based on the assay results. These 16 target rhAT-medication combinations passed all assay specifications at time-zero and 18 hours. Because all 18-hour time point sample results showed little to no difference from initial results, intermediate time points were not evaluated. These data indicated that rhAT (100 IU/mL in normal saline) was found to be unaffected by 16 of the 18 studied medications when co-infused in a common IV line at real-world concentrations.

Keywords: Antithrombin (ATIII), ATryn, medication.